Pfizer’s Atirmociclib Hits Study Goal as Q4 Non-COVID Revenues Rise 9%
Pfizer’s phase II trial of CDK4 inhibitor atirmociclib in second-line metastatic breast cancer met its primary endpoint, bolstering the company’s oncology pipeline. Non-COVID operational revenue rose 9% in Q4 offsetting pandemic sales declines, while U.S. cash prices for Xeljanz were up to 82% higher than U.K. levels.
1. Atirmociclib Phase II Study Success
Pfizer reported its phase II trial of CDK4 inhibitor atirmociclib in second-line metastatic breast cancer met its primary endpoint, strengthening its oncology pipeline and validating its investment in next-generation targeted therapies.
2. Q4 Operational Revenue and Pipeline Expansion
Non-COVID operational revenue rose 9% in Q4, offsetting declines in pandemic-related sales, while the integration of Seagen programs doubled Pfizer’s oncology pipeline to 60 programs and established a $10 billion revenue target by 2030.
3. U.S. Cash Pricing vs. U.K. for Xeljanz
Listings on the U.S. TrumpRx portal show cash prices for Pfizer’s arthritis pill Xeljanz up to 82% higher than U.K. National Health Service reimbursement rates, underscoring potential regulatory and pricing pressures.